Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acurx Pharmaceuticals, Inc. (ACXP)
USD1.75
+0.10 (+6.06%)
US NASDAQ Healthcare Biotechnology
Address
259 Liberty Avenue 10305
Staten Island, NY, US
Staten Island, NY, US
CEO
David Luci
Website
acurxpharma.com
IPO
2021-06-25
CIK 1736243 ISIN US00510M2035
Description
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.75
+0.10 (+6.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
123.8K
Beta
-2.09
Float Shares
1.30M
Free Float %
82.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.31% | +4.31% | -16.48% | +14.74% | -56.22% | -12.45% | -72.44% | -96.40% | -98.62% | -98.62% | -98.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
1.75
DCF (Unlevered)
5,040.79
+287,945.2%
DCF (Levered)
5,040.76
+287,943.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.45
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+69.8% ★ Q1'26: +71.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+76.0% Q1'26: +171.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 10.34M (-100.0%)
|
276.0K
276.0K – 276.0K
-97.3% YoY
|
3.54M
3.54M – 3.54M
+1,180.8% YoY
|
25.31M
25.31M – 25.31M
+615.9% YoY
|
47.49M
47.49M – 47.49M
+87.7% YoY
|
62.67M
62.67M – 62.67M
+32.0% YoY
|
| EBITDA |
—
|
-8.09M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.10M
|
-8.09M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-14.10M
est: -14.31M (+1.4%)
|
-7.97M
est: -9.06M (+12.1%)
|
-3.23M
-3.23M – -3.23M
+64.3% YoY
|
-3.13M
-3.13M – -3.13M
+3.1% YoY
|
-3.11M
-3.11M – -3.11M
+0.7% YoY
|
-2.73M
-2.73M – -2.73M
+12.3% YoY
|
1.74M
1.74M – 1.74M
+163.7% YoY
|
| SGA |
8.70M
|
6.26B
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-17.59
est: -16.80 (-4.7%)
|
-5.32
est: -6.05 (+12.0%)
|
-2.16
-2.16 – -2.16
+64.3% YoY
|
-2.09
-2.09 – -2.09
+3.1% YoY
|
-2.08
-2.08 – -2.08
+0.7% YoY
|
-1.82
-1.82 – -1.82
+12.3% YoY
|
1.16
1.16 – 1.16
+163.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
2.4K
Insider transactions (90d)
8
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David P. Luci | 1.35M | 13.20% | 1.30M | 50.1K | 1.30M | 10.00 | IN | United States of America | 2021-07-06 | ↗ |
| 2 | Robert J. DeLuccia | 1.33M | 13.00% | 1.32M | 3.8K | 1.32M | 10.00 | IN | United States of America | 2021-07-06 | ↗ |
| 3 | Armistice Capital, LLC | 880.0K | 7.59% | — | 880.0K | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 4 | Steven Boyd | 880.0K | 7.59% | — | 880.0K | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
-32 vs prev Q
New positions
0
Closed positions
31
Increased
0
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -7.6K (-100.0%) | — -2.4K (-100.0%) | 0.00% -0.637 pp | 0.00% +0.000 pp | USD— | 18 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 60.2K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
110.9K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+110,850
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 25,900 | 2.36 | 61.1K | 25,900 | D | ↗ |
| 2026-04-20 | Scodari Joseph C | Director | A-Award | A | Stock Option | 2,150 | 2.36 | 5.1K | 2,150 | D | ↗ |
| 2026-04-20 | Sailer Carl | Director | A-Award | A | Stock Option | 2,150 | 2.36 | 5.1K | 2,150 | D | ↗ |
| 2026-04-20 | LUCI DAVID P | Director / Officer | A-Award | A | Stock Option | 37,100 | 2.36 | 87.6K | 37,100 | D | ↗ |
| 2026-04-20 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 2,150 | 2.36 | 5.1K | 2,150 | D | ↗ |
| 2026-04-20 | Donohue James J. | Director | A-Award | A | Stock Option | 2,150 | 2.36 | 5.1K | 2,150 | D | ↗ |
| 2026-04-20 | DELUCCIA ROBERT J | Director | A-Award | A | Stock Option | 37,100 | 2.36 | 87.6K | 37,100 | D | ↗ |
| 2026-04-20 | DEAN JACK H | Director | A-Award | A | Stock Option | 2,150 | 2.36 | 5.1K | 2,150 | D | ↗ |
| 2025-02-05 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 145,500 | 0.80 | 116.1K | 145,500 | D | ↗ |
| 2025-02-05 | LUCI DAVID P | Director / Officer / 10% Owner | A-Award | A | Stock Option | 250,000 | 0.80 | 199.6K | 250,000 | D | ↗ |
| 2025-02-05 | DELUCCIA ROBERT J | Director / 10% Owner | A-Award | A | Stock Option | 250,000 | 0.80 | 199.6K | 250,000 | D | ↗ |
| 2025-01-06 | Scodari Joseph C | Director | P-Purchase | A | Warrants for Common Stock | 24,631 | 0.90 | 22.2K | 24,631 | D | ↗ |
| 2025-01-06 | Sailer Carl | Director | P-Purchase | A | Warrants for Common Stock | 24,631 | 0.90 | 22.2K | 24,631 | D | ↗ |
| 2025-01-06 | LUCI DAVID P | Director / Officer / 10% Owner | P-Purchase | A | Warrants for Common Stock | 49,261 | 0.90 | 44.3K | 49,261 | D | ↗ |
| 2025-01-06 | Donohue James J. | Director | P-Purchase | A | Warrants for Common Stock | 9,852 | 0.90 | 8.9K | 9,852 | D | ↗ |
| 2025-01-06 | DELUCCIA ROBERT J | Director / 10% Owner | P-Purchase | A | Warrants for Common Stock | 49,261 | 0.90 | 44.3K | 49,261 | D | ↗ |
| 2025-01-06 | DEAN JACK H | Director | P-Purchase | A | Common Stock | 9,852 | 1.02 | 10.0K | 21,776 | D | ↗ |
| 2024-06-17 | Scodari Joseph C | Director | A-Award | A | Stock Option | 12,000 | 2.38 | 28.6K | 12,000 | — | ↗ |
| 2024-06-17 | Sailer Carl | Director | A-Award | A | Stock Option | 12,000 | 2.38 | 28.6K | 12,000 | — | ↗ |
| 2024-06-17 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 12,000 | 2.38 | 28.6K | 12,000 | — | ↗ |
| 2024-06-17 | Donohue James J. | Director | A-Award | A | Stock Option | 12,000 | 2.38 | 28.6K | 12,000 | — | ↗ |
| 2024-06-17 | DEAN JACK H | Director | A-Award | A | Stock Option | 12,000 | 2.38 | 28.6K | 12,000 | — | ↗ |
| 2024-02-23 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 145,000 | 3.15 | 456.8K | 145,000 | — | ↗ |
| 2024-02-23 | LUCI DAVID P | Director / Officer / 10% Owner | A-Award | A | Stock Option | 250,000 | 3.15 | 787.5K | 250,000 | — | ↗ |
| 2024-02-23 | DELUCCIA ROBERT J | Director / 10% Owner | A-Award | A | Stock Option | 250,000 | 3.15 | 787.5K | 250,000 | — | ↗ |
| 2024-01-19 | Sailer Carl | Director | M-Exempt | D | Warrants for Common Stock | 19,737 | 3.55 | 70.1K | 0 | — | ↗ |
| 2024-01-03 | LUCI DAVID P | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 19,737 | 3.55 | 70.1K | 1,048,197 | — | ↗ |
| 2024-01-03 | DELUCCIA ROBERT J | Director / 10% Owner | M-Exempt | A | Common Stock | 19,737 | 3.55 | 70.1K | 960,935 | — | ↗ |
| 2023-12-22 | DELUCCIA ROBERT J | Director / 10% Owner | G-Gift | D | Common Stock | 30,000 | 0.00 | — | 941,198 | — | ↗ |
| 2023-12-12 | DELUCCIA ROBERT J | Director / 10% Owner | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 971,198 | — | ↗ |
| 2023-06-15 | Scodari Joseph C | Director | A-Award | A | Stock Option | 10,000 | 2.75 | 27.5K | 10,000 | — | ↗ |
| 2023-06-15 | Sailer Carl | Director | A-Award | A | Stock Option | 10,000 | 2.75 | 27.5K | 10,000 | — | ↗ |
| 2023-06-15 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 10,000 | 2.75 | 27.5K | 10,000 | — | ↗ |
| 2023-06-15 | Donohue James J. | Director | A-Award | A | Stock Option | 10,000 | 2.75 | 27.5K | 10,000 | — | ↗ |
| 2023-06-15 | DEAN JACK H | Director | A-Award | A | Stock Option | 10,000 | 2.75 | 27.5K | 10,000 | — | ↗ |
| 2023-02-13 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 75,000 | 3.41 | 255.8K | 75,000 | — | ↗ |
| 2023-02-13 | LUCI DAVID P | Director / Officer / 10% Owner | A-Award | A | Stock Option | 130,000 | 3.41 | 443.3K | 130,000 | — | ↗ |
| 2023-02-13 | DELUCCIA ROBERT J | Director / 10% Owner | A-Award | A | Stock Option | 130,000 | 3.41 | 443.3K | 130,000 | — | ↗ |
| 2022-07-27 | Sailer Carl | Director | P-Purchase | A | Warrants for Common Stock | 19,737 | 0.00 | — | 19,737 | — | ↗ |
| 2022-07-27 | LUCI DAVID P | Officer | P-Purchase | A | Warrants for Common Stock | 19,737 | 0.00 | — | 19,737 | — | ↗ |
| 2022-07-27 | DELUCCIA ROBERT J | Director / 10% Owner | P-Purchase | A | Common Stock | 19,737 | 3.80 | 75.0K | 1,051,198 | — | ↗ |
| 2021-12-02 | DELUCCIA ROBERT J | Director / 10% Owner | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 1,011,198 | — | ↗ |
| 2021-11-23 | Sailer Carl | Director | P-Purchase | A | Common Stock | 5,161 | 4.84 | 25.0K | 73,078 | — | ↗ |
| 2021-11-19 | LUCI DAVID P | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,200 | 4.80 | 25.0K | 1,008,723 | — | ↗ |
| 2021-11-19 | DELUCCIA ROBERT J | Director / 10% Owner | P-Purchase | A | Common Stock | 5,034 | 4.90 | 24.7K | 1,031,461 | — | ↗ |
| 2021-07-01 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 200,000 | 6.18 | 1.24M | 200,000 | — | ↗ |
| 2021-07-01 | Scodari Joseph C | Director | A-Award | A | Stock Option | 50,000 | 6.18 | 309.0K | 50,000 | — | ↗ |
| 2021-07-01 | Sailer Carl | Director | A-Award | A | Stock Option | 50,000 | 6.18 | 309.0K | 50,000 | — | ↗ |
| 2021-07-01 | LUCI DAVID P | Director / Officer / 10% Owner | A-Award | A | Stock Option | 500,000 | 6.18 | 3.09M | 500,000 | — | ↗ |
| 2021-07-01 | HARRISON THOMAS L | Director | A-Award | A | Stock Option | 50,000 | 6.18 | 309.0K | 50,000 | — | ↗ |
| 2021-07-01 | Donohue James J. | Director | A-Award | A | Stock Option | 50,000 | 6.18 | 309.0K | 50,000 | — | ↗ |
| 2021-07-01 | DELUCCIA ROBERT J | Director / 10% Owner | A-Award | A | Stock Option | 500,000 | 6.18 | 3.09M | 500,000 | — | ↗ |
| 2021-07-01 | DEAN JACK H | Director | A-Award | A | Stock Option | 50,000 | 6.18 | 309.0K | 50,000 | — | ↗ |
| 2021-06-29 | Shawah Robert G. | Officer | A-Award | A | Stock Option | 70,000 | 6.26 | 438.2K | 70,000 | — | ↗ |
| 2021-06-29 | Sailer Carl | Director | P-Purchase | A | Common Stock | 12,500 | 6.00 | 75.0K | 67,917 | — | ↗ |
| 2021-06-29 | LUCI DAVID P | Director / Officer / 10% Owner | A-Award | A | Stock Option | 350,000 | 6.26 | 2.19M | 350,000 | — | ↗ |
| 2021-06-29 | DELUCCIA ROBERT J | Director / 10% Owner | A-Award | A | Stock Option | 350,000 | 6.26 | 2.19M | 350,000 | — | ↗ |
| 2021-06-24 | Shawah Robert G. | Officer | — | D | Common Stock | 0 | 0.00 | — | 189,200 | — | ↗ |
| 2021-06-24 | Scodari Joseph C | Director | — | D | Common Stock | 0 | 0.00 | — | 3,077 | — | ↗ |
| 2021-06-24 | Sailer Carl | Director | — | I | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2021-06-24 | LUCI DAVID P | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 15,083 | — | ↗ |
| 2021-06-24 | HARRISON THOMAS L | Director | — | D | Common Stock | 0 | 0.00 | — | 1,539 | — | ↗ |
| 2021-06-24 | Donohue James J. | Director | — | D | Common Stock | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2021-06-24 | DELUCCIA ROBERT J | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,847 | — | ↗ |
| 2021-06-24 | DEAN JACK H | Director | — | I | Common Stock | 0 | 0.00 | — | 5,770 | — | ↗ |
| 2019-10-18 | DELUCCIA ROBERT J | Director / 10% Owner | — | D | Warrants for Common Stock | 3,125 | 4.00 | 12.5K | 0 | — | ↗ |
| 2019-08-08 | Shawah Robert G. | Officer | — | D | Warrants for Common Stock | 625 | 4.00 | 2.5K | 0 | — | ↗ |
| 2019-08-08 | Sailer Carl | Director | — | D | Warrants for Common Stock | 3,125 | 4.00 | 12.5K | 0 | — | ↗ |
| 2019-08-08 | DEAN JACK H | Director | — | D | Warrants for Common Stock | 1,875 | 4.00 | 7.5K | 0 | — | ↗ |
| 2019-03-29 | LUCI DAVID P | Director / Officer / 10% Owner | — | D | Warrants for Common Stock | 3,125 | 4.00 | 12.5K | 0 | — | ↗ |
| 2018-10-23 | Sailer Carl | Director | — | D | Warrants for Common Stock | 4,167 | 3.00 | 12.5K | 0 | — | ↗ |
| 2018-10-23 | LUCI DAVID P | Director / Officer / 10% Owner | — | D | Warrants for Common Stock | 7,500 | 3.00 | 22.5K | 0 | — | ↗ |
| 2018-10-23 | DELUCCIA ROBERT J | Director / 10% Owner | — | D | Warrants for Common Stock | 8,334 | 3.00 | 25.0K | 0 | — | ↗ |
| 2018-03-20 | Sailer Carl | Director | — | D | Warrants for Common Stock | 6,250 | 2.00 | 12.5K | 0 | — | ↗ |
| 2018-03-20 | LUCI DAVID P | Director / Officer / 10% Owner | — | D | Warrants for Common Stock | 6,250 | 2.00 | 12.5K | 0 | — | ↗ |
| 2018-03-20 | Donohue James J. | Director | — | D | Warrants for Common Stock | 6,250 | 2.00 | 12.5K | 0 | — | ↗ |
| 2018-03-20 | DELUCCIA ROBERT J | Director / 10% Owner | — | D | Warrants for Common Stock | 6,250 | 2.00 | 12.5K | 0 | — | ↗ |
| 2018-03-20 | DEAN JACK H | Director | — | D | Warrants for Common Stock | 3,125 | 2.00 | 6.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Robert J. DeLuccia Executive Chairman | 539.2K | 254.6K | — | — | — | 669.6K | 1.46M | 0.00% | ↗ |
| 2 | 2024 | David P. Luci President and Chief Executive Officer | 537.5K | 249.4K | — | — | — | 644.5K | 1.43M | 0.00% | ↗ |
| 3 | 2024 | Robert G. Shawah Chief Financial Officer | 395.8K | 137.8K | — | — | — | 373.8K | 907.5K | 0.00% | ↗ |
| 4 | 2023 | Robert J. DeLuccia Executive Chairman | 485.0K | 194.0K | — | — | — | 377.5K | 1.06M | 0.00% | ↗ |
| 5 | 2023 | David P. Luci President and Chief Executive Officer | 475.0K | 194.0K | — | — | — | 354.9K | 1.02M | 0.00% | ↗ |
| 6 | 2023 | Robert G. Shawah Chief Financial Officer | 375.0K | 95.3K | — | — | — | 204.8K | 675.0K | 0.00% | ↗ |
| 7 | 2022 | Robert J. DeLuccia Executive Chairman | 475.0K | 180.0K | — | — | — | 22.2K | 677.2K | 0.00% | ↗ |
| 8 | 2022 | David P. Luci President and Chief Executive Officer | 475.0K | 180.0K | — | — | — | — | 655.0K | 0.00% | ↗ |
| 9 | 2022 | Robert G. Shawah Chief Financial Officer | 300.0K | 75.0K | — | — | — | — | 375.0K | 0.00% | ↗ |
| 10 | 2021 | Robert J. DeLuccia Executive Chairman | 363.5K | 60.0K | 62.3K | 3.98M | — | 41.3K | 4.51M | 89.69% | ↗ |
| 11 | 2021 | David P. Luci President and Chief Executive Officer | 363.5K | 60.0K | 62.3K | 3.98M | — | 19.6K | 4.49M | 90.12% | ↗ |
| 12 | 2021 | David P. Luci President and Chief Executive Officer, Director | 2.00 | 60.0K | 62.3K | 3.98M | — | 19.6K | 4.49M | 90.12% | ↗ |
| 13 | 2021 | Robert G. Shawah Chief Financial Officer | 170.1K | 25.0K | — | 1.26M | — | 5.3K | 1.46M | 86.30% | ↗ |
| 14 | 2020 | Robert J. DeLuccia Executive Chairman | 3.00 | 20.8K | 274.8K | — | — | 45.0K | 617.6K | 44.50% | ↗ |
| 15 | 2020 | David P. Luci President and Chief Executive Officer, Director | 2.00 | 20.8K | 274.8K | — | — | 23.4K | 596.0K | 46.11% | ↗ |
| 16 | 2020 | Robert G. Shawah Chief Financial Officer | 4.00 | — | 62.5K | — | — | — | 152.5K | 40.98% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert J. DeLuccia | Co-Founder & Executive Chairman | 617.7K | male |
| David Luci | Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director | 575.4K | male |
| Robert G. Shawah | Co-Founder & Chief Financial Officer | 413.9K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACXP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
